%PDF-1.6
%
1 0 obj
<>
endobj
2 0 obj
<>stream
Issifou Yaya, Perrine Roux, Fabienne Marcellin, Linda Wittkop, Laure Esterle, Bruno Spire, Stéphanie Dominguez, Boni Armand Elegbe, Lionel Piroth, Philippe Sogni, Dominique Salmon-Ceron, Maria Patrizia Carrieri, the ANRS CO13 HEPAVIH Study Group
Evolution of patients’ socio-behavioral characteristics in the context of DAA: Results from the French ANRS CO13 HEPAVIH cohort of HIV-HCV co-infected patients
www.plosone.org
www.plosone.org
endstream
endobj
3 0 obj
<>/XObject<>>>/CropBox[0 0 612 792]/MediaBox[0 0 612 792]/Parent 12 0 R/Annots 13 0 R/Contents 14 0 R/TrimBox[0 0 612 792]>>
endobj
13 0 obj
[15 0 R 16 0 R 17 0 R 18 0 R 19 0 R 20 0 R 21 0 R 22 0 R 23 0 R 24 0 R 25 0 R 26 0 R 27 0 R 28 0 R 29 0 R 30 0 R]
endobj
15 0 obj
<>/Border[0 0 0]/Dest(Rpone.0199874.ref001)>>
endobj
16 0 obj
<>/Border[0 0 0]/Dest(Rpone.0199874.ref002)>>
endobj
17 0 obj
<>/Border[0 0 0]/Dest(Rpone.0199874.ref003)>>
endobj
18 0 obj
<>/Border[0 0 0]/Dest(Rpone.0199874.ref004)>>
endobj
19 0 obj
<>/Border[0 0 0]/Dest(Rpone.0199874.ref005)>>
endobj
20 0 obj
<>/Border[0 0 0]/Dest(Rpone.0199874.ref008)>>
endobj
21 0 obj
<>/Border[0 0 0]/Dest(Rpone.0199874.ref009)>>
endobj
22 0 obj
<>/Border[0 0 0]/Dest(Rpone.0199874.ref010)>>
endobj
23 0 obj
<>/Border[0 0 0]/Dest(Rpone.0199874.ref011)>>
endobj
24 0 obj
<>/Border[0 0 0]/Dest(Rpone.0199874.ref012)>>
endobj
25 0 obj
<>/Border[0 0 0]/Dest(Rpone.0199874.ref013)>>
endobj
26 0 obj
<>/Border[0 0 0]/Dest(Rpone.0199874.ref014)>>
endobj
27 0 obj
<>/Border[0 0 0]/Dest(Rpone.0199874.ref010)>>
endobj
28 0 obj
<>/Border[0 0 0]/Dest(Rpone.0199874.ref015)>>
endobj
29 0 obj
<>/Border[0 0 0]/Dest(Rpone.0199874.ref016)>>
endobj
30 0 obj
<>/Border[0 0 0]/A 31 0 R>>
endobj
31 0 obj
<>
endobj
14 0 obj
[32 0 R 33 0 R 34 0 R 35 0 R 36 0 R 37 0 R 38 0 R 39 0 R 40 0 R 41 0 R 42 0 R 43 0 R 44 0 R 45 0 R 46 0 R 47 0 R]
endobj
32 0 obj
<>stream
q
0.45 0.36 0.35 0.01 k
0 w
575.9997 506.6144 m
199.9998 506.6144 l
199.9998 507.1144 l
575.9997 507.1144 l
f*
0.83 0.64 0.02 0 k
307.7291 419.9244 m
312.4913 419.9244 l
h
f*
234.5953 367.937 m
239.3575 367.937 l
h
f*
294.3496 341.915 m
299.1118 341.915 l
h
f*
301.3228 341.915 m
306.085 341.915 l
h
f*
329.1024 276.9449 m
333.8079 276.9449 l
h
f*
339.0236 276.9449 m
343.7858 276.9449 l
h
f*
506.0976 250.9228 m
510.8598 250.9228 l
h
f*
513.1276 250.9228 m
522.652 250.9228 l
h
f*
267.9874 224.9008 m
277.5118 224.9008 l
h
f*
402.3496 185.8961 m
411.874 185.8961 l
h
f*
534.5575 172.9134 m
544.0819 172.9134 l
h
f*
509.9528 146.948 m
519.4772 146.948 l
h
f*
532.7433 107.9433 m
542.2677 107.9433 l
h
f*
544.5354 107.9433 m
554.0598 107.9433 l
h
f*
546.8031 94.9039 m
556.3276 94.9039 l
h
f*
0 g
1 j
1 J
9.5 0 0 9.5 200.0125 707.7543 cm
BT
/F0 1 Tf
1 TL
-0.0042 Tc
0 0 Td
(injection)Tj
3.8312 0 Td
(\(68.9%)Tj
3.3538 0 Td
(vs)Tj
1.2174 0 Td
(39.0%,)Tj
3.3001 0 Td
(p)Tj
/F5 1 Tf
[( )]TJ
/F0 1 Tf
(0.0001\))Tj
4.7025 0 Td
(and)Tj
1.8679 0 Td
(significant)Tj
4.607 0 Td
(liver)Tj
2.0231 0 Td
(fibrosis)Tj
3.3478 0 Td
(\(62.4%)Tj
3.3539 0 Td
(vs)Tj
1.2114 0 Td
(72.3%,)Tj
3.3061 0 Td
(p)Tj
0.7698 0 Td
(=)Tj
-36.892 -1.474 Td
(0.0293\).)Tj
3.8491 0 Td
(In)Tj
1.0443 0 Td
(multivariable)Tj
5.7588 0 Td
(analysis,)Tj
4.064 0 Td
(patients)Tj
3.6761 0 Td
(initiating)Tj
3.8312 0 Td
(DAA-based)Tj
5.2814 0 Td
(treatment)Tj
4.4101 0 Td
(were)Tj
2.3632 0 Td
(older)Tj
2.4109 0 Td
(than)Tj
-36.6891 -1.474 Td
(their)Tj
2.1364 0 Td
(PEG-IFN-based)Tj
7.2805 0 Td
(treatment)Tj
4.4101 0 Td
(counterparts)Tj
5.717 0 Td
(\(aOR)Tj
2.596 0 Td
(=)Tj
0.7996 0 Td
(1.17;)Tj
2.4169 0 Td
(95%CI)Tj
3.1927 0 Td
([1.13;)Tj
2.7034 0 Td
(1.22]\).)Tj
3.0256 0 Td
(Patients)Tj
-34.2782 -1.474 Td
(receiving)Tj
4.1654 0 Td
(DAA)Tj
2.2617 0 Td
(treatment)Tj
4.4101 0 Td
(were)Tj
2.3632 0 Td
(less)Tj
1.9753 0 Td
(likely)Tj
2.405 0 Td
(to)Tj
1.0503 0 Td
(report)Tj
2.7988 0 Td
(unstable)Tj
3.9566 0 Td
(housing)Tj
3.6701 0 Td
(\(0.46)Tj
2.4765 0 Td
([0.24;)Tj
2.6974 0 Td
(0.88]\),)Tj
3.0256 0 Td
(can-)Tj
-37.256 -1.474 Td
(nabis)Tj
2.578 0 Td
(use)Tj
1.8141 0 Td
(\(regular)Tj
3.6164 0 Td
(or)Tj
1.0981 0 Td
(daily)Tj
2.2438 0 Td
(use:0.50)Tj
4.0163 0 Td
([0.28;)Tj
2.6973 0 Td
(0.91];)Tj
2.6974 0 Td
(non-regular)Tj
5.2695 0 Td
(use:)Tj
2.0886 0 Td
(0.41)Tj
2.1424 0 Td
([0.22;)Tj
2.6974 0 Td
(0.77]\),)Tj
3.0316 0 Td
(and)Tj
1.8679 0 Td
(a)Tj
-37.8588 -1.474 Td
(history)Tj
3.133 0 Td
(of)Tj
1.0443 0 Td
(drug)Tj
2.1961 0 Td
(injection)Tj
3.8312 0 Td
(\(0.19)Tj
2.4766 0 Td
([0.12;)Tj
2.6974 0 Td
(0.31]\).)Tj
ET
Q
q
1 j
1 J
0 w
11.4998 0 0 11.4998 200.0125 607.1244 cm
BT
/F2 1 Tf
1 TL
-0.0035 Tc
0 0 Td
(Conclusion)Tj
ET
Q
q
1 j
1 J
0 w
9.5 0 0 9.5 200.0125 590.1165 cm
BT
/F0 1 Tf
1 TL
-0.0042 Tc
0 0 Td
(It)Tj
0.7757 0 Td
(is)Tj
0.931 0 Td
(possible)Tj
3.8372 0 Td
(that)Tj
1.8738 0 Td
(a)Tj
0.7639 0 Td
(majority)Tj
3.682 0 Td
(of)Tj
1.0504 0 Td
(patients)Tj
3.676 0 Td
(who)Tj
2.035 0 Td
(had)Tj
1.8679 0 Td
(socio-economic)Tj
7.0896 0 Td
(problems)Tj
4.2847 0 Td
(and/or)Tj
3.0197 0 Td
(a)Tj
0.7698 0 Td
(history)Tj
-35.6567 -1.474 Td
(of)Tj
1.0443 0 Td
(drug)Tj
2.1961 0 Td
(injection)Tj
3.8312 0 Td
(and/or)Tj
3.0256 0 Td
(a)Tj
0.7699 0 Td
(non-advanced)Tj
6.4808 0 Td
(disease)Tj
3.6224 0 Td
(stage)Tj
2.6377 0 Td
(were)Tj
2.3632 0 Td
(already)Tj
3.4553 0 Td
(treated)Tj
3.3001 0 Td
(for)Tj
1.3785 0 Td
(HCV)Tj
2.3155 0 Td
(in)Tj
0.9786 0 Td
(the)Tj
-37.3992 -1.474 Td
(PEG-IFN)Tj
4.2549 0 Td
(era.)Tj
1.9275 0 Td
(Today,)Tj
3.2464 0 Td
(patients)Tj
3.6821 0 Td
(with)Tj
1.9753 0 Td
(unstable)Tj
3.9506 0 Td
(housing)Tj
3.676 0 Td
(conditions)Tj
4.6608 0 Td
(are)Tj
1.6471 0 Td
(prescribed)Tj
4.8278 0 Td
(DAA)Tj
2.2617 0 Td
(less)Tj
1.9753 0 Td
(fre-)Tj
-38.0855 -1.474 Td
(quently)Tj
3.4015 0 Td
(than)Tj
2.1424 0 Td
(other)Tj
2.4766 0 Td
(populations.)Tj
5.5439 0 Td
(As)Tj
1.3786 0 Td
(HCV)Tj
2.3154 0 Td
(treatment)Tj
4.4041 0 Td
(is)Tj
0.931 0 Td
(prevention,)Tj
5.1083 0 Td
(improving)Tj
4.5056 0 Td
(access)Tj
3.3001 0 Td
(to)Tj
1.0443 0 Td
(DAA)Tj
-36.5518 -1.474 Td
(remains)Tj
3.7357 0 Td
(a)Tj
0.7698 0 Td
(major)Tj
2.6914 0 Td
(clinical)Tj
3.1689 0 Td
(and)Tj
1.8678 0 Td
(public)Tj
2.7929 0 Td
(health)Tj
2.9063 0 Td
(strategy,)Tj
4.0222 0 Td
(in)Tj
0.9846 0 Td
(particular)Tj
4.2788 0 Td
(for)Tj
1.3726 0 Td
(individuals)Tj
4.8159 0 Td
(with)Tj
1.9753 0 Td
(high-risk)Tj
-35.3822 -1.474 Td
(behaviors.)Tj
ET
Q
q
1 j
1 J
0 w
11.9999 0 0 11.9999 200.0125 450.9921 cm
BT
/F2 1 Tf
1 TL
-0.0033 Tc
0 0 Td
(Introduction)Tj
ET
Q
q
1 j
1 J
0 w
10 0 0 10 200.0125 433.9842 cm
BT
/F6 1 Tf
1 TL
-0.004 Tc
0 0 Td
(Chronic)Tj
3.5262 0 Td
(hepatitis)Tj
3.617 0 Td
(C)Tj
0.8844 0 Td
(virus)Tj
2.1997 0 Td
(\(HCV\))Tj
3.0274 0 Td
(infection)Tj
3.787 0 Td
(is)Tj
0.8504 0 Td
(an)Tj
1.2019 0 Td
(endemic)Tj
3.6567 0 Td
(disease)Tj
3.016 0 Td
(that)Tj
1.7745 0 Td
(affects)Tj
2.7382 0 Td
(approximately)Tj
5.9754 0 Td
(71)Tj
-36.2548 -1.2982 Td
(million)Tj
3.118 0 Td
(people)Tj
2.8573 0 Td
(worldwide)Tj
4.4561 0 Td
([)Tj
0.83 0.64 0.02 0 k
(1)Tj
0 g
(],)Tj
1.6044 0 Td
(with)Tj
1.9956 0 Td
(significant)Tj
4.388 0 Td
(regional)Tj
3.4866 0 Td
(variability.)Tj
4.4447 0 Td
(In)Tj
1.1111 0 Td
(recent)Tj
2.7043 0 Td
(decades,)Tj
3.5659 0 Td
(great)Tj
-33.732 -1.2983 Td
(progress)Tj
3.5943 0 Td
(has)Tj
1.542 0 Td
(been)Tj
2.126 0 Td
(made)Tj
2.4264 0 Td
(in)Tj
1.0318 0 Td
(treating)Tj
3.3279 0 Td
(chronic)Tj
3.2881 0 Td
(HCV)Tj
2.3471 0 Td
(infection.)Tj
4.0138 0 Td
(First-generation)Tj
6.6841 0 Td
(treatments)Tj
4.4957 0 Td
(were)Tj
-34.8772 -1.3039 Td
(mainly)Tj
2.9876 0 Td
(composed)Tj
4.3087 0 Td
(of)Tj
1.0148 0 Td
(pegylated)Tj
4.0081 0 Td
(interferon)Tj
4.269 0 Td
(\(PEG-IFN\))Tj
4.6998 0 Td
(and)Tj
1.7291 0 Td
(ribavirin)Tj
3.7077 0 Td
(and)Tj
1.7291 0 Td
(were)Tj
2.126 0 Td
(administered)Tj
5.4879 0 Td
(for)Tj
-36.0678 -1.2983 Td
(at)Tj
0.9524 0 Td
(least)Tj
1.9842 0 Td
(48)Tj
1.1679 0 Td
(weeks.)Tj
2.8346 0 Td
(The)Tj
1.7802 0 Td
(response)Tj
3.736 0 Td
(rate)Tj
1.7461 0 Td
(was)Tj
1.7008 0 Td
(6070%)Tj
3.3959 0 Td
(for)Tj
1.3833 0 Td
(genotypes)Tj
4.2236 0 Td
(2)Tj
0.6916 0 Td
(and)Tj
1.7348 0 Td
(3)Tj
0.6917 0 Td
(but)Tj
1.5534 0 Td
(lower)Tj
2.4547 0 Td
(for)Tj
1.3833 0 Td
(genotypes)Tj
-33.4145 -1.2982 Td
(1)Tj
0.6916 0 Td
(and)Tj
1.7348 0 Td
(4)Tj
0.6916 0 Td
([)Tj
0.83 0.64 0.02 0 k
(2)Tj
0 g
(].)Tj
1.6044 0 Td
(Moreover,)Tj
4.3937 0 Td
(PEG-IFN-based)Tj
6.6217 0 Td
(treatments)Tj
4.4957 0 Td
(had)Tj
1.7121 0 Td
(significant)Tj
4.388 0 Td
(side)Tj
1.7972 0 Td
(effects)Tj
2.7269 0 Td
(including)Tj
4.0422 0 Td
(flu-)Tj
-34.8999 -1.3039 Td
(like)Tj
1.6497 0 Td
(symptoms,)Tj
4.5864 0 Td
(asthenia,)Tj
3.7417 0 Td
(neuropsychiatric)Tj
6.9392 0 Td
(symptoms,)Tj
4.5864 0 Td
(hematological)Tj
5.8167 0 Td
(toxicity,)Tj
3.4299 0 Td
(rashes,)Tj
2.9253 0 Td
(and)Tj
1.7292 0 Td
(more)Tj
-35.4045 -1.2983 Td
(lifetime)Tj
3.2541 0 Td
(complications)Tj
5.8393 0 Td
([)Tj
0.83 0.64 0.02 0 k
(3)Tj
0 g
(,)Tj
0.83 0.64 0.02 0 k
(4)Tj
0 g
(].)Tj
-7.8972 -1.2983 Td
(The)Tj
1.7858 0 Td
(recent)Tj
2.7099 0 Td
(emergence)Tj
4.5411 0 Td
(of)Tj
1.0148 0 Td
(a)Tj
0.6519 0 Td
(new)Tj
1.8765 0 Td
(generation)Tj
4.5071 0 Td
(of)Tj
1.0148 0 Td
(treatmentsdirect-actin)Tj
9.8362 0 Td
(g)Tj
0.6859 0 Td
(antivirals)Tj
3.9005 0 Td
(\(DAA\))Tj
-33.7207 -1.2982 Td
(constitutes)Tj
4.5354 0 Td
(a)Tj
0.6519 0 Td
(revolution)Tj
4.371 0 Td
(in)Tj
1.0375 0 Td
(HCV)Tj
2.3414 0 Td
(care.)Tj
2.0976 0 Td
(DAA)Tj
2.3244 0 Td
(are)Tj
1.4513 0 Td
(more)Tj
2.3414 0 Td
(effective)Tj
3.5093 0 Td
(and)Tj
1.7291 0 Td
(better)Tj
2.5455 0 Td
(tolerated)Tj
3.7474 0 Td
(than)Tj
-32.6832 -1.304 Td
(PEG-IFN)Tj
4.0195 0 Td
(and)Tj
1.7291 0 Td
(ribavirin,)Tj
3.9344 0 Td
(and)Tj
1.7292 0 Td
(in)Tj
1.0374 0 Td
(8)Tj
0.6917 0 Td
(to)Tj
1.0261 0 Td
(24)Tj
1.1736 0 Td
(weeks)Tj
2.6078 0 Td
(a)Tj
0.652 0 Td
(sustained)Tj
3.9685 0 Td
(virological)Tj
4.4106 0 Td
(response)Tj
3.7304 0 Td
(\(SVR\))Tj
2.6929 0 Td
(is)Tj
-33.4032 -1.2982 Td
(obtained)Tj
3.7303 0 Td
(in)Tj
1.0375 0 Td
(over)Tj
1.9786 0 Td
(90%)Tj
1.9275 0 Td
(of)Tj
1.0148 0 Td
(treated)Tj
2.9934 0 Td
(patients,)Tj
3.5943 0 Td
(including)Tj
4.0422 0 Td
(previously)Tj
4.354 0 Td
(difficult-to-treat)Tj
6.684 0 Td
(patients)Tj
3.3675 0 Td
(and)Tj
-34.7241 -1.2983 Td
(HIV-HCV)Tj
4.4957 0 Td
(co-infected)Tj
4.6998 0 Td
(patients)Tj
3.3732 0 Td
([)Tj
0.83 0.64 0.02 0 k
(5)Tj
0 g
()Tj
0.83 0.64 0.02 0 k
(8)Tj
0 g
(].)Tj
-11.3725 -1.3039 Td
(However,)Tj
4.0818 0 Td
(the)Tj
1.4684 0 Td
(costs)Tj
2.1713 0 Td
(of)Tj
1.0148 0 Td
(DAA)Tj
2.3244 0 Td
(are)Tj
1.4456 0 Td
(very)Tj
1.9276 0 Td
(high,)Tj
2.2337 0 Td
(and)Tj
1.7291 0 Td
(access)Tj
2.6475 0 Td
(varies)Tj
2.5285 0 Td
(across)Tj
2.6759 0 Td
(global)Tj
2.6306 0 Td
(regions.)Tj
3.3845 0 Td
(Even)Tj
2.2167 0 Td
(in)Tj
-35.6766 -1.2983 Td
(countries)Tj
3.9458 0 Td
(with)Tj
1.9955 0 Td
(a)Tj
0.6577 0 Td
(universal)Tj
3.8551 0 Td
(health)Tj
2.6758 0 Td
(system,)Tj
3.1635 0 Td
(restricted)Tj
3.9855 0 Td
(access)Tj
2.6475 0 Td
(is)Tj
0.8447 0 Td
(not)Tj
1.5761 0 Td
(uncommon)Tj
4.9209 0 Td
([)Tj
0.83 0.64 0.02 0 k
(9)Tj
0 g
(,)Tj
0.83 0.64 0.02 0 k
(10)Tj
0 g
(].)Tj
2.7779 0 Td
(Germany)Tj
-33.046 -1.2982 Td
(and)Tj
1.7291 0 Td
(the)Tj
1.4683 0 Td
(United)Tj
3.0217 0 Td
(Kingdom)Tj
4.0309 0 Td
(are)Tj
1.4456 0 Td
(two)Tj
1.7121 0 Td
(countries)Tj
3.9458 0 Td
(that)Tj
1.7802 0 Td
(immediately)Tj
5.1987 0 Td
(implemented)Tj
5.5389 0 Td
(universal)Tj
3.8551 0 Td
(access)Tj
2.6418 0 Td
(to)Tj
-36.3682 -1.3039 Td
(DAA)Tj
2.3243 0 Td
(treatment)Tj
4.1329 0 Td
([)Tj
0.83 0.64 0.02 0 k
(11)Tj
0 g
(],)Tj
2.0806 0 Td
(and)Tj
1.7292 0 Td
(all)Tj
1.1452 0 Td
(patients)Tj
3.3675 0 Td
(infected)Tj
3.4186 0 Td
(with)Tj
2.0012 0 Td
(HCV)Tj
2.3414 0 Td
(are)Tj
1.4513 0 Td
(treated)Tj
2.9991 0 Td
(unconditionally.)Tj
6.7974 0 Td
(In)Tj
1.1055 0 Td
(both)Tj
-34.8942 -1.2983 Td
(the)Tj
1.4683 0 Td
(PEG-IFN)Tj
4.0195 0 Td
(and)Tj
1.7291 0 Td
(DAA)Tj
2.3244 0 Td
(eras,)Tj
2.0353 0 Td
(in)Tj
1.0374 0 Td
(some)Tj
2.3301 0 Td
(countries,)Tj
4.1726 0 Td
(the)Tj
1.4683 0 Td
(most)Tj
2.2054 0 Td
(common)Tj
3.8494 0 Td
(barriers)Tj
3.3222 0 Td
(to)Tj
1.0261 0 Td
(initiating)Tj
3.8834 0 Td
(HCV)Tj
-34.8715 -1.2983 Td
(treatment)Tj
4.1328 0 Td
(in)Tj
1.0375 0 Td
(HIV-HCV)Tj
4.4957 0 Td
(co-infected)Tj
4.7055 0 Td
(patients)Tj
3.3676 0 Td
(include)Tj
3.1804 0 Td
(psychoactive)Tj
5.3121 0 Td
(substance)Tj
4.1045 0 Td
(use,)Tj
1.7575 0 Td
(and)Tj
1.7348 0 Td
(social)Tj
-33.8284 -1.3039 Td
(instability)Tj
4.1669 0 Td
(such)Tj
2.0636 0 Td
(as)Tj
1.0148 0 Td
(homelessness)Tj
5.5785 0 Td
(or)Tj
1.0998 0 Td
(imprisonment)Tj
5.9698 0 Td
([)Tj
0.83 0.64 0.02 0 k
(12)Tj
0 g
(].)Tj
-18.6972 -1.2983 Td
(In)Tj
1.1111 0 Td
(May)Tj
2.0013 0 Td
(2016)Tj
2.1203 0 Td
(the)Tj
1.474 0 Td
(French)Tj
3.0387 0 Td
(Ministry)Tj
3.685 0 Td
(of)Tj
1.0148 0 Td
(Health)Tj
2.914 0 Td
(announced)Tj
4.7112 0 Td
(universal)Tj
3.8551 0 Td
(access)Tj
2.6418 0 Td
(to)Tj
1.0262 0 Td
(DAA)Tj
2.3244 0 Td
([)Tj
0.83 0.64 0.02 0 k
(13)Tj
0 g
(].)Tj
-33.1141 -1.2982 Td
(Before)Tj
2.8119 0 Td
(this)Tj
1.6724 0 Td
(announcement,)Tj
6.497 0 Td
(initiating)Tj
3.8834 0 Td
(DAA)Tj
2.3244 0 Td
(treatment)Tj
4.1329 0 Td
(was)Tj
1.7008 0 Td
(subject)Tj
3.016 0 Td
(to)Tj
1.0262 0 Td
(a)Tj
0.6576 0 Td
(multidisciplinary)Tj
7.0639 0 Td
(con-)Tj
-34.7865 -1.2983 Td
(sultation)Tj
3.7076 0 Td
(meeting)Tj
3.464 0 Td
(\(RCP\))Tj
2.7439 0 Td
(which)Tj
2.6532 0 Td
(evaluated)Tj
3.9855 0 Td
(its)Tj
1.1508 0 Td
(relevance)Tj
3.9685 0 Td
(on)Tj
1.2756 0 Td
(a)Tj
0.652 0 Td
(case)Tj
1.8595 0 Td
(by)Tj
1.1849 0 Td
(case)Tj
1.8595 0 Td
(basis)Tj
2.1543 0 Td
([)Tj
0.83 0.64 0.02 0 k
(14)Tj
0 g
(].)Tj
2.0749 0 Td
(Clinical)Tj
3.3165 0 Td
(cri-)Tj
-36.0507 -1.3039 Td
(teria)Tj
2.0125 0 Td
(were)Tj
2.1203 0 Td
(usually)Tj
3.0218 0 Td
(the)Tj
1.4683 0 Td
(basis)Tj
2.1486 0 Td
(for)Tj
1.389 0 Td
(selecting)Tj
3.6737 0 Td
(patients)Tj
3.3675 0 Td
(for)Tj
1.389 0 Td
(DAA)Tj
2.3244 0 Td
(treatment.)Tj
4.3596 0 Td
(We)Tj
1.6101 0 Td
(do)Tj
1.2529 0 Td
(not)Tj
1.5761 0 Td
(know)Tj
2.4548 0 Td
(to)Tj
1.0261 0 Td
(what)Tj
-35.1947 -1.2983 Td
(extent)Tj
2.6758 0 Td
(other)Tj
2.3471 0 Td
(patient)Tj
3.0104 0 Td
(characteristics,)Tj
6.1285 0 Td
(especially)Tj
4.0195 0 Td
(those)Tj
2.3357 0 Td
(that)Tj
1.7801 0 Td
(may)Tj
1.9276 0 Td
(limit)Tj
2.1146 0 Td
(patients')Tj
3.583 0 Td
(acceptability)Tj
5.2157 0 Td
(of,)Tj
-35.138 -1.2982 Td
(engagement)Tj
5.0683 0 Td
(in,)Tj
1.2642 0 Td
(or)Tj
1.0942 0 Td
(adherence)Tj
4.3256 0 Td
(to)Tj
1.0262 0 Td
(treatment,)Tj
4.3596 0 Td
(influenced)Tj
4.4447 0 Td
(selection)Tj
3.719 0 Td
(for)Tj
1.3833 0 Td
(DAA)Tj
2.3244 0 Td
(initiation)Tj
3.9232 0 Td
([)Tj
0.83 0.64 0.02 0 k
(10)Tj
0 g
(,)Tj
0.83 0.64 0.02 0 k
(15)Tj
0 g
(].)Tj
-32.9327 -1.304 Td
(Injecting)Tj
3.7927 0 Td
(drug)Tj
2.1089 0 Td
(use)Tj
1.5307 0 Td
(is)Tj
0.8504 0 Td
(a)Tj
0.652 0 Td
(well)Tj
1.8198 0 Td
(described)Tj
4.0535 0 Td
(factor)Tj
2.5455 0 Td
(which)Tj
2.6476 0 Td
(can)Tj
1.6271 0 Td
(delay)Tj
2.3073 0 Td
(HCV)Tj
2.3414 0 Td
(treatment)Tj
4.1386 0 Td
(initiation)Tj
3.9231 0 Td
([)Tj
0.83 0.64 0.02 0 k
(16)Tj
0 g
(].)Tj
2.075 0 Td
(It)Tj
-36.4136 -1.2982 Td
(has)Tj
1.542 0 Td
(also)Tj
1.7688 0 Td
(been)Tj
2.1203 0 Td
(reported)Tj
3.6623 0 Td
(that)Tj
1.7745 0 Td
(HCV-infected)Tj
5.896 0 Td
(patients)Tj
3.3732 0 Td
(with)Tj
1.9956 0 Td
(psychiatric)Tj
4.5638 0 Td
(disorders)Tj
3.9401 0 Td
(are)Tj
1.4457 0 Td
(less)Tj
1.6157 0 Td
(likely)Tj
2.3527 0 Td
(to)Tj
ET
Q
q
1 j
1 J
0 w
576 737.1 m
36 737.1 l
36 737.6 l
576 737.6 l
f*
36 741.2598 107.1496 23.6976 re
W* n
q
107.0929 0 0 23.6409 36 741.3165 cm
q
/I0 Do
Q
Q
Q
q
0 0 612 792 re
W* n
1 j
1 J
0 w
7.9999 0 0 7.9999 247.0677 745.7952 cm
BT
/F0 1 Tf
1 TL
-0.005 Tc
0 0 Td
(Socio-b)Tj
3.3236 0 Td
(ehavioral)Tj
4.1953 0 Td
(characteris)Tj
4.8048 0 Td
(tics)Tj
1.6937 0 Td
(between)Tj
3.9402 0 Td
(pegylated)Tj
4.252 0 Td
(-interferon)Tj
4.6913 0 Td
(treated)Tj
3.2812 0 Td
(and)Tj
1.8567 0 Td
(DAA-tr)Tj
2.9551 0 Td
(eated)Tj
2.6788 0 Td
(patients)Tj
ET
Q
q
1 j
1 J
0 w
36 48.0002 m
576 48.0002 l
576 47.5002 l
36 47.5002 l
f*
0.83 0.64 0.02 0 k
81.5811 34.9228 m
237.8835 34.9228 l
h
f*
0 g
7.9999 0 0 7.9999 36 36 cm
BT
/F0 1 Tf
1 TL
-0.005 Tc
0 0 Td
(PLOS)Tj
2.8559 0 Td
(ONE)Tj
2.3669 0 Td
(|)Tj
0.83 0.64 0.02 0 k
0.4748 0 Td
(https://doi.or)Tj
5.4142 0 Td
(g/10.137)Tj
3.8198 0 Td
(1/journal.po)Tj
5.1236 0 Td
(ne.01998)Tj
4.089 0 Td
(74)Tj
0 g
2.0906 0 Td
(July)Tj
1.9701 0 Td
(5,)Tj
1.0417 0 Td
(2018)Tj
35.894 0 Td
(2)Tj
0.7654 0 Td
(/)Tj
0.496 0 Td
(15)Tj
/F8 1 Tf
-0.025 Tc
-66.402 84.0904 Td
(Hepatitis)Tj
3.4441 0 Td
(\(ANRS\),)Tj
3.2811 0 Td
(with)Tj
1.7858 0 Td
(the)Tj
1.3678 0 Td
(participation)Tj
4.7764 0 Td
(of)Tj
0.9496 0 Td
(Abbott)Tj
-15.6048 -1.3748 Td
(France;)Tj
2.9126 0 Td
(Glaxo-Smith)Tj
4.6063 0 Td
(-)Tj
0.5244 0 Td
(Kline;)Tj
2.2536 0 Td
(Roche;)Tj
2.8205 0 Td
(Schering-)Tj
-13.1174 -1.3749 Td
(Plough;)Tj
3.0543 0 Td
(and)Tj
1.5874 0 Td
(INSERM's)Tj
4.0182 0 Td
(`Programme)Tj
4.8543 0 Td
(Cohortes)Tj
-13.5142 -1.3748 Td
(TGIR'.)Tj
2.5441 0 Td
(The)Tj
1.5874 0 Td
(funders)Tj
3.0472 0 Td
(had)Tj
1.5875 0 Td
(no)Tj
1.1622 0 Td
(role)Tj
1.6157 0 Td
(in)Tj
0.8859 0 Td
(study)Tj
2.2677 0 Td
(design,)Tj
-14.6977 -1.3748 Td
(data)Tj
1.7929 0 Td
(collection)Tj
3.7347 0 Td
(and)Tj
1.5945 0 Td
(analysis)Tj
2.9622 0 Td
(,)Tj
0.4464 0 Td
(decision)Tj
3.2883 0 Td
(to)Tj
0.9496 0 Td
(publish,)Tj
3.1465 0 Td
(or)Tj
-17.9151 -1.3748 Td
(preparation)Tj
4.4433 0 Td
(of)Tj
0.9496 0 Td
(the)Tj
1.3677 0 Td
(manuscript.)Tj
4.6347 0 Td
(There)Tj
2.3174 0 Td
(was)Tj
1.7078 0 Td
(no)Tj
-15.4205 -1.3748 Td
(additional)Tj
3.7913 0 Td
(external)Tj
3.1323 0 Td
(funding)Tj
3.0402 0 Td
(received)Tj
3.2953 0 Td
(for)Tj
1.2614 0 Td
(this)Tj
1.5591 0 Td
(study.)Tj
/F7 1 Tf
-16.0796 -2.126 Td
(Competing)Tj
4.3795 0 Td
(interests)Tj
3.3307 0 Td
(:)Tj
/F8 1 Tf
0.4819 0 Td
(LW)Tj
1.4953 0 Td
(reports)Tj
2.8772 0 Td
(grants)Tj
2.5725 0 Td
(from)Tj
-15.1371 -1.3748 Td
(ANRS,)Tj
2.6716 0 Td
(during)Tj
2.615 0 Td
(the)Tj
1.3677 0 Td
(conduct)Tj
3.2103 0 Td
(of)Tj
0.9496 0 Td
(the)Tj
1.3677 0 Td
(study;)Tj
2.4945 0 Td
(grants)Tj
-14.6764 -1.3748 Td
(from)Tj
2.0126 0 Td
(Inserm)Tj
2.8488 0 Td
(Aviesan,)Tj
3.3237 0 Td
(personal)Tj
3.4016 0 Td
(fees)Tj
1.7433 0 Td
(from)Tj
2.0055 0 Td
(BMS,)Tj
-15.3355 -1.3749 Td
(Janssen,)Tj
3.5008 0 Td
(Gilead)Tj
2.5086 0 Td
(and)Tj
1.5875 0 Td
(MSD)Tj
2.0834 0 Td
(outside)Tj
2.9339 0 Td
(the)Tj
1.3677 0 Td
(submitted)Tj
-13.9819 -1.3748 Td
(work;)Tj
2.2889 0 Td
(LP)Tj
1.219 0 Td
(reports)Tj
2.8771 0 Td
(personal)Tj
3.4016 0 Td
(fees)Tj
1.7434 0 Td
(from)Tj
2.0055 0 Td
(Bristol)Tj
2.5937 0 Td
(Myers)Tj
-16.1292 -1.3748 Td
(Squibb,)Tj
3.0543 0 Td
(Gilead,)Tj
2.7355 0 Td
(Viiv)Tj
1.5519 0 Td
(Healthcare,)Tj
4.3725 0 Td
(MSD,)Tj
2.3103 0 Td
(Pfizer,)Tj
-14.0245 -1.3748 Td
(Gilead,)Tj
2.7354 0 Td
(Janssen)Tj
3.274 0 Td
(Cilag,)Tj
2.2465 0 Td
(outside)Tj
2.9339 0 Td
(the)Tj
1.3677 0 Td
(submitted)Tj
3.9473 0 Td
(work.)Tj
-16.5048 -1.3748 Td
(This)Tj
1.7787 0 Td
(does)Tj
2.0126 0 Td
(not)Tj
1.4244 0 Td
(alter)Tj
1.8142 0 Td
(our)Tj
1.4741 0 Td
(adherence)Tj
4.0535 0 Td
(to)Tj
0.9496 0 Td
(PLOS)Tj
2.3316 0 Td
(ONE)Tj
-15.8387 -1.3748 Td
(policies)Tj
3.0118 0 Td
(on)Tj
1.1622 0 Td
(sharing)Tj
2.9835 0 Td
(data)Tj
1.7929 0 Td
(and)Tj
ET
endstream
endobj
33 0 obj
<>stream
endstream
endobj
34 0 obj
<>stream
endstream
endobj
35 0 obj
<>stream
endstream
endobj
36 0 obj
<>stream
endstream
endobj
37 0 obj
<>stream
endstream
endobj
38 0 obj
<>stream
endstream
endobj
39 0 obj
<>stream
endstream
endobj
40 0 obj
<>stream
endstream
endobj
41 0 obj
<>stream
endstream
endobj
42 0 obj
<>stream
endstream
endobj
43 0 obj
<>stream
endstream
endobj
44 0 obj
<>stream
endstream
endobj
45 0 obj
<>stream
endstream
endobj
46 0 obj
<>stream
endstream
endobj
47 0 obj
<>stream
BT
10.5378 62.717 Td
(materials.)Tj
ET
Q
endstream
endobj
48 0 obj
<>/XObject<>>>/CropBox[0 0 612 792]/MediaBox[0 0 612 792]/Parent 12 0 R/Annots 50 0 R/Contents 51 0 R/TrimBox[0 0 612 792]>>
endobj
50 0 obj
[52 0 R 53 0 R 54 0 R 55 0 R 56 0 R 57 0 R 58 0 R 59 0 R]
endobj
52 0 obj
<>/Border[0 0 0]/Dest(Rpone.0199874.ref017)>>
endobj
53 0 obj
<>/Border[0 0 0]/Dest(Rpone.0199874.ref018)>>
endobj
54 0 obj
<>/Border[0 0 0]/Dest(Rpone.0199874.ref019)>>
endobj
55 0 obj
<>/Border[0 0 0]/Dest(Rpone.0199874.ref020)>>
endobj
56 0 obj
<>/Border[0 0 0]/Dest(Rpone.0199874.ref014)>>
endobj
57 0 obj
<>/Border[0 0 0]/Dest(Rpone.0199874.ref021)>>
endobj
58 0 obj
<>/Border[0 0 0]/Dest(Rpone.0199874.g001)>>
endobj
59 0 obj
<>/Border[0 0 0]/A 60 0 R>>
endobj
60 0 obj
<>
endobj
51 0 obj
[61 0 R 62 0 R 63 0 R 64 0 R 65 0 R 66 0 R 67 0 R 68 0 R 69 0 R 70 0 R]
endobj
61 0 obj
<>stream
q
0.83 0.64 0.02 0 k
406.9417 706.337 m
416.4661 706.337 l
h
f*
258.8031 654.3496 m
268.3276 654.3496 l
h
f*
417.1465 641.3102 m
426.6709 641.3102 l
h
f*
403.1433 628.3276 m
412.6677 628.3276 l
h
f*
458.2488 615.3449 m
467.7732 615.3449 l
h
f*
412.2709 404.9008 m
421.7953 404.9008 l
h
f*
250.3559 120.926 m
269.915 120.926 l
h
f*
0 g
1 j
1 J
0 w
10 0 0 10 200.0125 707.4141 cm
BT
/F6 1 Tf
1 TL
-0.004 Tc
0 0 Td
(benefit)Tj
2.9763 0 Td
(from)Tj
2.2053 0 Td
(HCV)Tj
2.3415 0 Td
(treatment.)Tj
4.3653 0 Td
(In)Tj
1.1055 0 Td
(France,)Tj
3.1748 0 Td
(Roux)Tj
2.3414 0 Td
(et)Tj
0.9411 0 Td
(al)Tj
0.9014 0 Td
([)Tj
0.83 0.64 0.02 0 k
(17)Tj
0 g
(])Tj
1.8538 0 Td
(also)Tj
1.7688 0 Td
(reported)Tj
3.6567 0 Td
(that)Tj
1.7801 0 Td
(people)Tj
2.8517 0 Td
(who)Tj
1.9389 0 Td
(inject)Tj
-34.2026 -1.3039 Td
(drugs)Tj
2.4717 0 Td
(\(PWID\))Tj
3.5036 0 Td
(\(currently)Tj
4.2236 0 Td
(or)Tj
1.0999 0 Td
(in)Tj
1.0318 0 Td
(the)Tj
1.474 0 Td
(past\))Tj
2.1656 0 Td
(were)Tj
2.126 0 Td
(less)Tj
1.6101 0 Td
(likely)Tj
2.3527 0 Td
(to)Tj
1.0262 0 Td
(be)Tj
1.1508 0 Td
(treated)Tj
2.9991 0 Td
(for)Tj
1.3833 0 Td
(HCV)Tj
2.347 0 Td
(in)Tj
1.0375 0 Td
(the)Tj
1.4683 0 Td
(PEG-IFN)Tj
-33.4712 -1.2982 Td
(era.)Tj
1.6724 0 Td
(However,)Tj
4.0762 0 Td
(a)Tj
0.6576 0 Td
(previous)Tj
3.6453 0 Td
(study)Tj
2.3925 0 Td
(using)Tj
2.3867 0 Td
(data)Tj
1.9162 0 Td
(collected)Tj
3.7417 0 Td
(during)Tj
2.9254 0 Td
(the)Tj
1.4683 0 Td
(ANRS)Tj
2.7383 0 Td
(CO13)Tj
2.5795 0 Td
(HEPAVIH)Tj
4.6034 0 Td
(cohort)Tj
-34.8035 -1.2983 Td
(showed)Tj
3.2371 0 Td
(no)Tj
1.2699 0 Td
(relationship)Tj
4.9776 0 Td
(between)Tj
3.5206 0 Td
(a)Tj
0.6406 0 Td
(history)Tj
2.9991 0 Td
(of)Tj
1.0034 0 Td
(injecting)Tj
3.7077 0 Td
(drug)Tj
2.1033 0 Td
(use)Tj
1.5251 0 Td
(and)Tj
1.7177 0 Td
(access)Tj
2.6362 0 Td
(to)Tj
1.0148 0 Td
(PEG-IFN+)Tj
4.5921 0 Td
(ribavi-)Tj
-34.9452 -1.2983 Td
(rin)Tj
1.4059 0 Td
(treatment)Tj
4.1329 0 Td
([)Tj
0.83 0.64 0.02 0 k
(18)Tj
0 g
(].)Tj
2.0806 0 Td
(While)Tj
2.6476 0 Td
(the)Tj
1.4683 0 Td
(HCV)Tj
2.3471 0 Td
(infection)Tj
3.7927 0 Td
(epidemic)Tj
3.8891 0 Td
(in)Tj
1.0375 0 Td
(France,)Tj
3.1748 0 Td
(and)Tj
1.7291 0 Td
(more)Tj
2.3414 0 Td
(generally)Tj
3.8324 0 Td
(in)Tj
-33.8794 -1.3039 Td
(Europe,)Tj
3.3618 0 Td
(has)Tj
1.5421 0 Td
(mainly)Tj
2.9877 0 Td
(been)Tj
2.1259 0 Td
(driven)Tj
2.812 0 Td
(by)Tj
1.1792 0 Td
(injecting)Tj
3.719 0 Td
(drug)Tj
2.1146 0 Td
(use)Tj
1.5307 0 Td
([)Tj
0.83 0.64 0.02 0 k
(19)Tj
0 g
(],)Tj
2.075 0 Td
(recent)Tj
2.7099 0 Td
(data)Tj
1.9162 0 Td
(suggest)Tj
3.1181 0 Td
(the)Tj
1.474 0 Td
(epidemiol-)Tj
-32.6662 -1.2982 Td
(ogy)Tj
1.644 0 Td
(of)Tj
1.0148 0 Td
(HCV)Tj
2.3471 0 Td
(infection)Tj
3.7927 0 Td
(in)Tj
1.0318 0 Td
(HIV)Tj
2.024 0 Td
(patients)Tj
3.3675 0 Td
(is)Tj
0.8504 0 Td
(changing)Tj
3.9004 0 Td
([)Tj
0.83 0.64 0.02 0 k
(20)Tj
0 g
(].)Tj
2.075 0 Td
(Given)Tj
2.6305 0 Td
(that)Tj
1.7802 0 Td
(national)Tj
3.5036 0 Td
(HCV)Tj
2.3414 0 Td
(guidelines)Tj
-32.3034 -1.2983 Td
(strongly)Tj
3.4695 0 Td
(recommend)Tj
5.0854 0 Td
(access)Tj
2.6475 0 Td
(to)Tj
1.0261 0 Td
(HCV)Tj
2.3414 0 Td
(treatment)Tj
4.1386 0 Td
(for)Tj
1.3833 0 Td
(HIV)Tj
2.0239 0 Td
(patients)Tj
3.3676 0 Td
([)Tj
0.83 0.64 0.02 0 k
(14)Tj
0 g
(])Tj
1.8538 0 Td
(and)Tj
1.7291 0 Td
(that)Tj
1.7802 0 Td
(free)Tj
1.7234 0 Td
(access)Tj
2.6476 0 Td
(to)Tj
-35.2174 -1.3039 Td
(DAA)Tj
2.3243 0 Td
(has)Tj
1.5421 0 Td
(been)Tj
2.1203 0 Td
(possible)Tj
3.4129 0 Td
(since)Tj
2.2393 0 Td
(May)Tj
2.0069 0 Td
(2016)Tj
2.1203 0 Td
(in)Tj
1.0375 0 Td
(France,)Tj
3.1691 0 Td
(we)Tj
1.3323 0 Td
(aimed)Tj
2.6872 0 Td
(to)Tj
1.0262 0 Td
(compare)Tj
3.719 0 Td
(the)Tj
1.4683 0 Td
(socio-behavioral)Tj
-30.2057 -1.2983 Td
(characteristics)Tj
5.9016 0 Td
(of)Tj
1.0148 0 Td
(patients)Tj
3.3676 0 Td
(initiating)Tj
3.8834 0 Td
(HCV)Tj
2.3471 0 Td
(treatment)Tj
4.1329 0 Td
(in)Tj
1.0375 0 Td
(the)Tj
1.4683 0 Td
(ANRS)Tj
2.7382 0 Td
(CO13)Tj
2.5796 0 Td
(HEPAVIH)Tj
4.6034 0 Td
(cohort)Tj
-33.0744 -1.2983 Td
(between)Tj
3.5262 0 Td
(those)Tj
2.3358 0 Td
(receiving)Tj
3.8664 0 Td
(PEG-IFN-based)Tj
6.6217 0 Td
(treatment)Tj
4.1385 0 Td
(and)Tj
1.7292 0 Td
(those)Tj
2.3357 0 Td
(receiving)Tj
3.8664 0 Td
(DAA,)Tj
2.5512 0 Td
(our)Tj
1.6214 0 Td
(hypothesis)Tj
-32.5925 -1.3039 Td
(being)Tj
2.4321 0 Td
(that)Tj
1.7744 0 Td
(patients')Tj
3.583 0 Td
(characteristics)Tj
5.9074 0 Td
(may)Tj
1.9275 0 Td
(play)Tj
1.8709 0 Td
(an)Tj
1.2019 0 Td
(important)Tj
4.2859 0 Td
(role)Tj
1.7688 0 Td
(in)Tj
1.0318 0 Td
(caregiver-patient)Tj
6.9959 0 Td
(relation-)Tj
-32.7796 -1.2982 Td
(ships,)Tj
2.4774 0 Td
(as)Tj
1.0148 0 Td
(well)Tj
1.8198 0 Td
(as)Tj
1.0148 0 Td
(in)Tj
1.0375 0 Td
(access)Tj
2.6476 0 Td
(to)Tj
1.0204 0 Td
(and)Tj
1.7348 0 Td
(retention)Tj
3.9061 0 Td
(in)Tj
1.0318 0 Td
(the)Tj
1.474 0 Td
(HCV)Tj
2.3414 0 Td
(and)Tj
1.7348 0 Td
(HIV)Tj
2.0183 0 Td
(care)Tj
1.8708 0 Td
(systems.)Tj
-25.9481 -1.2983 Td
(Our)Tj
1.8708 0 Td
(objective)Tj
3.7814 0 Td
(was)Tj
1.6951 0 Td
(not)Tj
1.5761 0 Td
(simply)Tj
2.8856 0 Td
(to)Tj
1.0262 0 Td
(identify)Tj
3.2938 0 Td
(possible)Tj
3.4072 0 Td
(barriers)Tj
3.3279 0 Td
(to)Tj
1.0261 0 Td
(accessing)Tj
3.9288 0 Td
(DAA)Tj
2.3244 0 Td
(treatment,)Tj
4.3597 0 Td
(but)Tj
-35.6993 -1.3039 Td
(also)Tj
1.7688 0 Td
(to)Tj
1.0204 0 Td
(highlight)Tj
3.8154 0 Td
(the)Tj
1.4684 0 Td
(change)Tj
3.0444 0 Td
(in)Tj
1.0374 0 Td
(the)Tj
1.4684 0 Td
(profile)Tj
2.8403 0 Td
(of)Tj
1.0148 0 Td
(HIV-HCV)Tj
4.4957 0 Td
(co-infected)Tj
4.6998 0 Td
(patients)Tj
3.3732 0 Td
(initiating)Tj
3.8778 0 Td
(HCV)Tj
-33.9248 -1.2983 Td
(treatment.)Tj
ET
Q
q
1 j
1 J
0 w
11.9999 0 0 11.9999 200.0125 480.0188 cm
BT
/F2 1 Tf
1 TL
-0.0033 Tc
0 0 Td
(Methods)Tj
/F10 1 Tf
0 -1.5023 Td
(Study)Tj
2.6173 0 Td
(design)Tj
2.915 0 Td
(and)Tj
1.7905 0 Td
(population)Tj
ET
Q
q
1 j
1 J
0 w
10 0 0 10 200.0125 444.9826 cm
BT
/F6 1 Tf
1 TL
-0.004 Tc
0 0 Td
(ANRS)Tj
2.7382 0 Td
(CO13)Tj
2.5795 0 Td
(HEPAVIH)Tj
4.6034 0 Td
(is)Tj
0.8448 0 Td
(a)Tj
0.6576 0 Td
(multicenter)Tj
4.8642 0 Td
(observational)Tj
5.5842 0 Td
(cohort)Tj
2.8517 0 Td
(initiated)Tj
3.5546 0 Td
(in)Tj
1.0318 0 Td
(France)Tj
2.948 0 Td
(in)Tj
1.0375 0 Td
(2005)Tj
-33.2955 -1.2982 Td
(among)Tj
2.9933 0 Td
(HIV-HCV)Tj
4.4957 0 Td
(co-infected)Tj
4.7055 0 Td
(patients)Tj
3.3676 0 Td
(to)Tj
1.0261 0 Td
(characterize)Tj
5.0286 0 Td
(the)Tj
1.4684 0 Td
(natural)Tj
3.0784 0 Td
(history)Tj
3.0103 0 Td
(of)Tj
1.0148 0 Td
(co-infection)Tj
5.074 0 Td
(in)Tj
-35.2627 -1.2983 Td
(terms)Tj
2.4944 0 Td
(of)Tj
1.0148 0 Td
(both)Tj
2.058 0 Td
(morbidity)Tj
4.2406 0 Td
(and)Tj
1.7291 0 Td
(mortality)Tj
3.9174 0 Td
(and)Tj
1.7292 0 Td
(their)Tj
2.1089 0 Td
(determinants,)Tj
5.7657 0 Td
(and)Tj
1.7291 0 Td
(to)Tj
1.0261 0 Td
(better)Tj
2.5455 0 Td
(understand)Tj
4.7849 0 Td
(the)Tj
-35.1437 -1.3039 Td
(interactions)Tj
4.9662 0 Td
(between)Tj
3.532 0 Td
(the)Tj
1.4683 0 Td
(two)Tj
1.7064 0 Td
(viruses)Tj
2.9877 0 Td
(and)Tj
1.7292 0 Td
(treatments)Tj
4.4957 0 Td
([)Tj
0.83 0.64 0.02 0 k
(21)Tj
0 g
(].)Tj
2.0806 0 Td
(ANRS)Tj
2.7383 0 Td
(CO13)Tj
2.5795 0 Td
(HEPAVIH)Tj
4.6034 0 Td
(recruited)Tj
-32.8873 -1.2983 Td
(outpatients)Tj
4.6941 0 Td
(from)Tj
2.1997 0 Td
(32)Tj
1.1678 0 Td
(clinical)Tj
3.0671 0 Td
(centers)Tj
3.0671 0 Td
(in)Tj
1.0261 0 Td
(France)Tj
2.9423 0 Td
(who)Tj
1.9333 0 Td
(were)Tj
2.1203 0 Td
(aged)Tj
2.0636 0 Td
(18)Tj
1.1678 0 Td
(or)Tj
1.0885 0 Td
(over,)Tj
2.1997 0 Td
(had)Tj
1.7008 0 Td
(both)Tj
2.0523 0 Td
(chronic)Tj
3.2825 0 Td
(hep-)Tj
-35.773 -1.2982 Td
(atitis)Tj
2.1429 0 Td
(C)Tj
0.8844 0 Td
(and)Tj
1.7292 0 Td
(HIV)Tj
2.0239 0 Td
(infection,)Tj
4.0195 0 Td
(had)Tj
1.7064 0 Td
(detectable)Tj
4.2236 0 Td
(plasma)Tj
3.0331 0 Td
(HCV)Tj
2.347 0 Td
(RNA,)Tj
2.4889 0 Td
(were)Tj
2.1203 0 Td
(positive)Tj
3.3165 0 Td
(for)Tj
1.3833 0 Td
(anti-HCV)Tj
4.2462 0 Td
(anti-)Tj
-35.6652 -1.3039 Td
(bodies,)Tj
3.0387 0 Td
(and)Tj
1.7291 0 Td
(agreed)Tj
2.863 0 Td
(to)Tj
1.0261 0 Td
(participate)Tj
4.473 0 Td
(in)Tj
1.0375 0 Td
(the)Tj
1.4684 0 Td
(cohort)Tj
2.8516 0 Td
(\(a)Tj
0.9978 0 Td
(signed)Tj
2.8119 0 Td
(letter)Tj
2.2791 0 Td
(of)Tj
1.0148 0 Td
(informed)Tj
3.9741 0 Td
(consent)Tj
3.3335 0 Td
(being)Tj
-32.8986 -1.2983 Td
(provided\).)Tj
1.1962 -1.2983 Td
(Patient)Tj
3.05 0 Td
(recruitment)Tj
4.9946 0 Td
(for)Tj
1.3833 0 Td
(this)Tj
1.6781 0 Td
(cohort)Tj
2.8517 0 Td
(included)Tj
3.7133 0 Td
(three)Tj
2.2677 0 Td
(phases:)Tj
-21.1349 -1.8992 Td
()Tj
0.7823 0 Td
(The)Tj
1.7802 0 Td
(first)Tj
1.8084 0 Td
(phase)Tj
2.4832 0 Td
(between)Tj
3.5263 0 Td
(December)Tj
4.3483 0 Td
(2005)Tj
2.1203 0 Td
(and)Tj
1.7348 0 Td
(December)Tj
4.3483 0 Td
(2008)Tj
2.1203 0 Td
(recruited)Tj
3.8551 0 Td
(adult)Tj
2.2507 0 Td
(HIV-positive)Tj
-30.3759 -1.3039 Td
(patients,)Tj
3.5943 0 Td
(who)Tj
1.9389 0 Td
(were)Tj
2.1203 0 Td
(also)Tj
1.7688 0 Td
(either)Tj
2.5285 0 Td
(chronically)Tj
4.6715 0 Td
(infected)Tj
3.4185 0 Td
(by)Tj
1.1849 0 Td
(HCV)Tj
2.3414 0 Td
(at)Tj
0.9524 0 Td
(enrollment)Tj
4.6545 0 Td
(or)Tj
1.0998 0 Td
(had)Tj
1.7065 0 Td
(a)Tj
0.6576 0 Td
(negative)Tj
-32.6379 -1.2983 Td
(HCV)Tj
2.3414 0 Td
(RNA)Tj
2.262 0 Td
(test)Tj
1.6044 0 Td
(by)Tj
1.1792 0 Td
(PCR)Tj
2.0637 0 Td
(six)Tj
1.3152 0 Td
(months)Tj
3.2825 0 Td
(after)Tj
2.0353 0 Td
(ending)Tj
2.999 0 Td
(HCV)Tj
2.3471 0 Td
(treatment)Tj
4.1329 0 Td
(\(PEG-IFN\),)Tj
-26.345 -1.8992 Td
()Tj
0.7823 0 Td
(The)Tj
1.7802 0 Td
(second)Tj
3.0103 0 Td
(phase,)Tj
2.7099 0 Td
(from)Tj
2.2054 0 Td
(September)Tj
4.4787 0 Td
(2011)Tj
2.126 0 Td
(to)Tj
1.0261 0 Td
(March)Tj
2.8686 0 Td
(2016,)Tj
2.3471 0 Td
(recruited)Tj
3.8551 0 Td
(both)Tj
2.0579 0 Td
(individuals)Tj
4.6488 0 Td
(who)Tj
-33.1141 -1.2982 Td
(spontaneously)Tj
5.9527 0 Td
(cleared)Tj
3.0728 0 Td
(HCV)Tj
2.3414 0 Td
(before)Tj
2.7439 0 Td
(the)Tj
1.4683 0 Td
(enrolment,)Tj
4.6318 0 Td
(and)Tj
1.7291 0 Td
(HIV-HCV)Tj
4.4957 0 Td
(infected)Tj
3.4243 0 Td
(patients)Tj
3.3675 0 Td
(who)Tj
1.9389 0 Td
(ini-)Tj
-35.1664 -1.3039 Td
(tiated)Tj
2.4661 0 Td
(HCV)Tj
2.3471 0 Td
(treatment)Tj
4.1329 0 Td
(with)Tj
2.0012 0 Td
(triple)Tj
2.3414 0 Td
(therapy)Tj
3.2485 0 Td
(\(PEG-IFN)Tj
4.3597 0 Td
(+ribavirin)Tj
4.2859 0 Td
(+)Tj
0.7994 0 Td
(either)Tj
2.5342 0 Td
(telaprevir)Tj
4.0251 0 Td
(or)Tj
-32.5415 -1.2983 Td
(boceprevir\),)Tj
-0.7823 -1.8992 Td
()Tj
0.7823 0 Td
(The)Tj
1.7802 0 Td
(third)Tj
2.211 0 Td
(phase,)Tj
2.7099 0 Td
(from)Tj
2.2053 0 Td
(May)Tj
2.0013 0 Td
(2014)Tj
2.1259 0 Td
(to)Tj
1.0205 0 Td
(November)Tj
4.4674 0 Td
(2015,)Tj
2.347 0 Td
(was)Tj
1.6951 0 Td
(an)Tj
1.2076 0 Td
(additional)Tj
4.2746 0 Td
(recruitment)Tj
4.9946 0 Td
(phase,)Tj
-33.0404 -1.2983 Td
(where)Tj
2.6475 0 Td
(patients)Tj
3.3676 0 Td
(who)Tj
1.9389 0 Td
(were)Tj
2.1259 0 Td
(already)Tj
3.1068 0 Td
(receiving,)Tj
4.0932 0 Td
(or)Tj
1.0998 0 Td
(were)Tj
2.1203 0 Td
(scheduled)Tj
4.2066 0 Td
(to)Tj
1.0262 0 Td
(receive)Tj
3.0103 0 Td
(DAA)Tj
2.3244 0 Td
(within)Tj
2.812 0 Td
(six)Tj
-33.8795 -1.3039 Td
(months,)Tj
3.5036 0 Td
(were)Tj
2.126 0 Td
(recruited.)Tj
-5.2157 -1.8992 Td
(In)Tj
1.1111 0 Td
(France,)Tj
3.1748 0 Td
(PEG-IFN+)Tj
4.5978 0 Td
(ribavirin)Tj
3.7077 0 Td
(first)Tj
1.8085 0 Td
(became)Tj
3.2485 0 Td
(available)Tj
3.668 0 Td
(in)Tj
1.0318 0 Td
(2000.)Tj
2.3527 0 Td
(Boceprevir)Tj
4.5581 0 Td
(and)Tj
1.7291 0 Td
(Telaprevir)Tj
-32.1843 -1.2983 Td
(became)Tj
3.2484 0 Td
(available)Tj
3.668 0 Td
(in)Tj
1.0375 0 Td
(2010.)Tj
2.3471 0 Td
(All)Tj
1.3946 0 Td
(three)Tj
2.2677 0 Td
(regimens)Tj
3.8948 0 Td
(were)Tj
2.126 0 Td
(replaced)Tj
3.5886 0 Td
(from)Tj
2.2054 0 Td
(2014)Tj
2.1203 0 Td
(onwards)Tj
3.651 0 Td
(with)Tj
2.0012 0 Td
(DAA.)Tj
-32.3544 -1.2982 Td
(In)Tj
1.1055 0 Td
(the)Tj
1.4683 0 Td
(present)Tj
3.1578 0 Td
(study,)Tj
2.6135 0 Td
(we)Tj
1.3209 0 Td
(included)Tj
3.7077 0 Td
(all)Tj
1.1452 0 Td
(cohort)Tj
2.8517 0 Td
(patients)Tj
3.3618 0 Td
(who)Tj
1.9389 0 Td
(had)Tj
1.7008 0 Td
(received)Tj
3.5319 0 Td
(or)Tj
1.0942 0 Td
(were)Tj
2.1203 0 Td
(still)Tj
1.6328 0 Td
(receiving)Tj
-33.9475 -1.3039 Td
(HCV)Tj
2.3414 0 Td
(treatment,)Tj
4.3653 0 Td
(whether)Tj
3.4752 0 Td
(PEG-IFN-based)Tj
6.6217 0 Td
(in)Tj
1.0375 0 Td
(the)Tj
1.4683 0 Td
(first)Tj
1.8029 0 Td
(phase)Tj
2.4831 0 Td
(of)Tj
1.0148 0 Td
(the)Tj
1.474 0 Td
(cohort)Tj
2.8516 0 Td
(or)Tj
1.0999 0 Td
(DAA-based)Tj
4.9265 0 Td
(in)Tj
1.0375 0 Td
(the)Tj
-35.9997 -1.2983 Td
(third)Tj
2.211 0 Td
(phase)Tj
2.4831 0 Td
(\()Tj
0.83 0.64 0.02 0 k
(Fig)Tj
1.8198 0 Td
(1)Tj
0 g
(\).)Tj
-5.3177 -1.2983 Td
(We)Tj
1.61 0 Td
(preferred)Tj
3.9402 0 Td
(to)Tj
1.0261 0 Td
(exclude)Tj
3.2542 0 Td
(Phase)Tj
2.5284 0 Td
(2)Tj
0.6917 0 Td
(patients)Tj
3.3675 0 Td
(from)Tj
2.211 0 Td
(this)Tj
1.6725 0 Td
(comparison)Tj
4.9776 0 Td
(for)Tj
1.3833 0 Td
(two)Tj
1.7121 0 Td
(reasons:)Tj
3.4469 0 Td
(first,)Tj
2.0353 0 Td
(a)Tj
0.6519 0 Td
(very)Tj
-35.7049 -1.3039 Td
(small)Tj
2.3243 0 Td
(sample)Tj
3.0218 0 Td
(were)Tj
2.1259 0 Td
(eligible)Tj
3.0614 0 Td
(for)Tj
1.389 0 Td
(this)Tj
1.6724 0 Td
(study,)Tj
2.6136 0 Td
(mainly)Tj
2.9933 0 Td
(patients)Tj
3.3676 0 Td
(in)Tj
1.0374 0 Td
(a)Tj
0.652 0 Td
(severe)Tj
2.6759 0 Td
(state)Tj
2.0352 0 Td
(of)Tj
1.0148 0 Td
(illness)Tj
2.6759 0 Td
(and)Tj
1.7292 0 Td
(patients)Tj
-34.3897 -1.2982 Td
(who)Tj
1.9388 0 Td
(were)Tj
2.1203 0 Td
(very)Tj
1.9276 0 Td
(unresponsive)Tj
5.5275 0 Td
(to)Tj
1.0261 0 Td
(Phase)Tj
2.5229 0 Td
(1)Tj
0.6973 0 Td
(treatment)Tj
4.1385 0 Td
(\(ie)Tj
1.2473 0 Td
(PEG-IFN+Ribavirin\))Tj
8.6796 0 Td
(due)Tj
1.6951 0 Td
(to)Tj
1.0261 0 Td
(the)Tj
1.4741 0 Td
(high)Tj
ET
Q
q
1 j
1 J
0 w
576 737.1 m
36 737.1 l
36 737.6 l
576 737.6 l
f*
36 741.2598 107.1496 23.6976 re
W* n
q
107.0929 0 0 23.6409 36 741.3165 cm
q
/I0 Do
Q
Q
Q
q
0 0 612 792 re
W* n
1 j
1 J
0 w
7.9999 0 0 7.9999 247.0677 745.7952 cm
BT
/F0 1 Tf
1 TL
-0.005 Tc
0 0 Td
(Socio-b)Tj
3.3236 0 Td
(ehavioral)Tj
4.1953 0 Td
(characteris)Tj
4.8048 0 Td
(tics)Tj
1.6937 0 Td
(between)Tj
3.9402 0 Td
(pegylated)Tj
4.252 0 Td
(-interferon)Tj
4.6913 0 Td
(treated)Tj
3.2812 0 Td
(and)Tj
1.8567 0 Td
(DAA-tr)Tj
2.9551 0 Td
(eated)Tj
2.6788 0 Td
(patients)Tj
ET
Q
q
1 j
1 J
0 w
36 48.0002 m
576 48.0002 l
576 47.5002 l
36 47.5002 l
f*
0.83 0.64 0.02 0 k
81.5811 34.9228 m
237.8835 34.9228 l
h
f*
0 g
7.9999 0 0 7.9999 36 36 cm
BT
/F0 1 Tf
1 TL
-0.005 Tc
0 0 Td
(PLOS)Tj
2.8559 0 Td
(ONE)Tj
2.3669 0 Td
(|)Tj
0.83 0.64 0.02 0 k
0.4748 0 Td
(https://doi.or)Tj
5.4142 0 Td
(g/10.137)Tj
3.8198 0 Td
(1/journal.po)Tj
5.1236 0 Td
(ne.01998)Tj
4.089 0 Td
(74)Tj
0 g
2.0906 0 Td
(July)Tj
1.9701 0 Td
(5,)Tj
1.0417 0 Td
(2018)Tj
35.894 0 Td
(3)Tj
0.7654 0 Td
(/)Tj
ET
endstream
endobj
62 0 obj
<>stream
endstream
endobj
63 0 obj
<>stream
endstream
endobj
64 0 obj
<>stream
endstream
endobj
65 0 obj
<>stream
endstream
endobj
66 0 obj
<>stream
endstream
endobj
67 0 obj
<>stream
endstream
endobj
68 0 obj
<>stream
endstream
endobj
69 0 obj
<>stream
endstream
endobj
70 0 obj
<>stream
BT
66.402 0 Td
(15)Tj
ET
Q
endstream
endobj
71 0 obj
<>/XObject<>>>/CropBox[0 0 612 792]/MediaBox[0 0 612 792]/Parent 12 0 R/Annots 73 0 R/Contents 74 0 R/TrimBox[0 0 612 792]>>
endobj
72 0 obj
<>stream
xy-GU60#*S4Q@AqVPAŁI GTFH!A@Pd" bL*2w{}ν}]GիVzWUG#4@#4@#4@#4@#4@#4@#4@#4@#4@#4@#4@#p>F88
Toc>Eguֳg4EIOzy睷?䶺hFhFhFhEr)WNwy~%y~iL\rYμT,wLySUjYU 99W]MTceX%b|M~ՉD*c\D~k:Jk]Sl?D\jH%ַA9oYػw